| Product NDC: | 0024-5860 |
| Proprietary Name: | Clolar |
| Non Proprietary Name: | clofarabine |
| Active Ingredient(s): | 1 mg/mL & nbsp; clofarabine |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0024-5860 |
| Labeler Name: | sanofi-aventis U.S. LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021673 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20130401 |
| Package NDC: | 0024-5860-01 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 BOX (0024-5860-01) > 20 mL in 1 VIAL, SINGLE-USE |
| NDC Code | 0024-5860-01 |
| Proprietary Name | Clolar |
| Package Description | 1 VIAL, SINGLE-USE in 1 BOX (0024-5860-01) > 20 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 0024-5860 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | clofarabine |
| Dosage Form Name | INJECTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20130401 |
| Marketing Category Name | NDA |
| Labeler Name | sanofi-aventis U.S. LLC |
| Substance Name | CLOFARABINE |
| Strength Number | 1 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |